A quantitative study has been made of the metabolism of S-carboxymethyl-L-cysteine (CMC) and its sulphoxides in volunteers by HPLC. Precolumn derivatization was applied prior to gradient reversed phase HPLC separation and fluorescence detection. For CMC and its metabolites containing a primary amino group the reagent 9-fluorenylmethylchloroformate was used. The other metabolites of CMC were derivatized at their carboxylic group with 1-pyrenyldiazomethane to give stable fluorescent products.
Urine samples were collected for 8 h after oral administration of 1.125 g CMC to 33 healthy volunteers. Elimination of CMC in urine as sulphoxides did not account for more than 1% of the dose in any of the volunteers. Thus, CMC-sulphoxide metabolites are not quantitatively important. Recovery of the original substance in 8-hour urines ranged from 10 to 30% and a further 2 to 20% was recovered as the metabolite thiodiglycolic acid.
Oral doses of 0.19, 1.125, and 2.25 g CMC in a second group of 12 healthy volunteers did not reveal dose dependence of the urinary excretion of the sulphoxides or of thiodiglycolic acid.
Serum concentration-time-curves of CMC, (S)- and (R)-CMC sulphoxide were measured in a group of 9 healthy volunteers. The CMC sulphoxides in serum reached 1.5% of the parent substance after 4 hours. The ratio of CMC to its sulphoxide metabolites was similar in serum and urine. Pharmacogenetic polymorphism of sulphoxidation was not confirmed by the specific HPLC methods used.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Mitchell SC, Waring RH, Haley CS, Idle JR, Smith RL (1984) Genetic aspects of the polymodally distributed sulfoxidation of S-carboxymethyl-L-cysteine in man. Br J Clin Pharmacol 18: 507–521
Turnbull LB, Teng L, Kinzie JM, Pitts JE, Pinchbeck FM, Bruce RB (1978) Excretion and biotransformation of carboxymethylcysteine in rat, dog, monkey and man. Xenobiotica 13: 621–628
Waring RH, Mitchell SC, Shah RR, Idle JR, Smith RL (1982) Polymorphic sulfoxidation of S-carboxymethyl-L-cysteine in man. Biochem Pharmacol 31: 3151–3154
Waring RH (1980) Variation in human metabolism of S-carboxymethylcysteine. Eur J Drug Metab Pharmacokinet 5: 49–52
Emery P, Panayi GS, Huston G, Welsh KI, Mitchell SC, Shah RR, Idle JR, Smith RL, Waring RH (1984) D-Penicillamine induced toxicity in rheumatoid arthritis: The role of sulfoxidation status and HLA-DR3. J Rheumatol 11: 626–632
Scadding GK, Ayesh R, Brostoff J, Mitchell SC, Waring RH, Smith RL (1988) Poor sulfoxidation ability in patients with food sensitivity. Br Med J 297: 105–107
Olumu AB, Vickers CR, Waring RH, Clements D, Babbs C, Warnes TW, Elias E (1988) High incidence of poor sulfoxidation in patients with primary biliary cirrhosis. N Engl J Med 318: 1089–1092
Toennies G, Kolb JJ (1951) Techniques and reagents for paper chromatography. Anal Chem 23: 823–826
Brockmöller J, Simane S, Roots I (1988) HPLC-detection of carbocysteine and its sulfoxides. Drug Metabol Drug Interact 6: 447–456
Einarsson S, Josefsson B, Lagerkvist S (1983) Determination of amino acids with 9-fluorenylmethyl chloroformate and reversed phase high-performance liquid chromatography. J Chromatogr 282: 609–618
Brockmöller J, Staffeldt B, Simane S, Roots I (1989) Sulfoxidation of carbocystein: Methods for analysis of pharmacokinetics and its genetics. Eur J Clin Pharmacol 36 [Suppl]: 70
Nimura N, Kinoshita T, Yoshida T, Uetake A, Nakai C (1988) 1-Pyrenyldiazomethane as a fluorescent labeling reagent for liquid chromatographic determination of carboxylic acids. Anal Chem 60: 2067–2070
Meese CO (1987) S-Carboxymethyl-L-cysteine (R)- and (S)-sulfoxide. Arch Pharm 320: 473–474
Lutz D, Gielsdorf W, Rasper J, Jaeger H, Albring M, Eisler G, Niebch G (1985) Untersuchungen zur Bioverfügbarkeit und Pharmakokinetik zweier Carbocistein-Zubereitungen nach Einfach- und Mehrfachdosierung. Arzneim-Forsch/Drug Res 35: 163–166
Küpfer A, Idle JR (1990) False positives with current carbocisteine protocol for sulphoxidation phenotyping Lancet I; 335: 1107
Meese CO, Specht D, Fischer P (1990) Revision of S-carboxymethyl-L-cysteine metabolism by 13C-NMR spectroscopy. Fresenius J Anal Chem 337: 63–64
Woolfson AD, Millership JS, Karim IA (1987) Determination of the sulfoxides of S-carboxymethyl-L-cysteine by high-performance liquid chromatography with electrochemical detection. Analyst 112: 1421–1425
About this article
Cite this article
Brockmöller, J., Staffeldt, B. & Roots, I. Evaluation of proposed sulphoxidation pathways of carbocysteine in man by HPLC quantification. Eur J Clin Pharmacol 40, 387–392 (1991). https://doi.org/10.1007/BF00265849
- drug metabolism